Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spheramine Titan/Schering.

Donald Grosset1, Katherine Grosset

  • 1Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, UK. d.grosset@clinmed.gla.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|July 28, 2005
PubMed
Summary

Spheramine, a novel cell therapy for Parkinson's disease, uses dopamine-producing cells on microcarriers. Phase II trials were underway in 2005, with completion anticipated in late 2006.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype-phenotype correlation in PRKN-associated Parkinson's disease.

NPJ Parkinson's disease·2024
Same author

Two sample Mendelian Randomisation using an outcome from a multilevel model of disease progression.

European journal of epidemiology·2024
Same author

Addressing Comorbidities in People with Parkinson's Disease: Considerations From An Expert Panel.

Journal of Parkinson's disease·2024
Same author

Genome-wide Analysis of Motor Progression in Parkinson Disease.

Neurology. Genetics·2023
Same author

Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.

Brain communications·2023
Same author

Genetics of validated Parkinson's disease subtypes in the Oxford Discovery and Tracking Parkinson's cohorts.

Journal of neurology, neurosurgery, and psychiatry·2022

Area of Science:

  • Neuroscience
  • Cell Therapy
  • Regenerative Medicine

Background:

  • Parkinson's disease is a progressive neurodegenerative disorder.
  • Current treatments manage symptoms but do not halt disease progression.
  • Cell-based therapies offer potential for neuroprotection and functional recovery.

Purpose of the Study:

  • To evaluate the safety and efficacy of Spheramine for advanced Parkinson's disease.
  • To assess the potential of dopamine-producing cells to restore neuronal function.

Main Methods:

  • Spheramine consists of microcarriers coated with human retinal pigment epithelial cells producing dopamine.
  • Phase II clinical trials were conducted to assess the therapeutic potential.
  • Patient outcomes were monitored during the trial period.

Main Results:

  • Phase II trials were ongoing as of March 2005.
  • Trial completion was projected for the second half of 2006.
  • Data on efficacy and safety were expected upon trial conclusion.

Conclusions:

  • Spheramine represents a promising cell-based therapeutic approach for Parkinson's disease.
  • Further clinical evaluation is necessary to establish its long-term benefits.
  • The successful completion of Phase II trials will inform future development.

Related Experiment Videos